Quinuclidine carbamate derivatives and their use as M3...

Details Quinuclidine carbamate derivatives and their use as M3... Quinuclidine carbamate derivatives and their use as M3...

2007-12-25

2007-12-25

Owens, Amelia A. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S135000, C546S137000

Reexamination Certificate

active

10404395

ABSTRACT:
A compound which is a carbamate of formula:wherein R1 representsR2 represents a benzyl, phenethyl, furan-2-ylmethyl, furan-3-ylmethyl, thiophen-2-ylmethyl or thiophen-3-ylmethyl group or a straight or branched alkyl group having 3 to 8 carbon atoms, an alkenyl group having 3 to 8 carbon atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p is 1 or 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt may be of formula:

REFERENCES:
patent: 2762796 (1956-09-01), Morel et al.
patent: 3714357 (1973-01-01), Gueremy et al.
patent: 6916828 (2005-07-01), Farrerons Gallemi et al.
patent: 2004/0063950 (2004-04-01), Farrerons Gallemi et al.
patent: 2004/0235887 (2004-11-01), Farrerons Gallemi et al.
patent: 2004/0266816 (2004-12-01), Albero et al.
patent: 2005/0043349 (2005-02-01), Catena Ruiz et al.
patent: 2155320 (1993-08-01), None
patent: 0 424 021 (1991-04-01), None
patent: 0 747 355 (1996-12-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 2 012 964 (1970-03-01), None
patent: 1 246 606 (1971-09-01), None
patent: 09-328469 (1997-12-01), None
patent: WO93/15080 (1993-08-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 02/00652 (2002-01-01), None
patent: WO02/051841 (2002-07-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO02/053564 (2002-07-01), None
patent: WO 2004/000840 (2003-12-01), None
patent: WO 2004/005285 (2004-01-01), None
van Zwieten et al. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy, 1995, 9(1): 159-67.
Xu et al. Chemical & Pharmaceutical Bulletin, 1998, 46(2): 231-41.
Eglen, RM et al, Therapeutic opportunities from muscarinic receptor research, Trends in Pharm. Sci. 22(8), Aug. 2001, 409-414.
Wallis, RM et al, Muscarinic antagonists in te development for disorders of smooth muscle function, PMID: 10069502 (1999).
White, Muscarinic receptors in human airways, PMID: 7751523 (1995).
Brown, J.H. and Taylor, P. (2001). “Muscarinic Receptor Agonists and Antagonists,” Chapter 7In The Pharmacological Basis of Therapeutics. Goodman et al. eds., McGraw Hill: 10th edition, pp. 155-173.
Eglen, R.M. and Hegde, S. S. (1997). “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential,”Drug News Perspect.10(8): 462-469.
Konzett, H. and Rossler, R. (1940). “Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur,”Arch. Exp. Path. Pharmacol.195: 71-74.
Rang, H.P. et al. (1995). “Cholinergic Transmission,” Chapter 6In Pharmacology. Churchill Livingstone, New York, NY. 3rd Edition, pp. 117-147.
Ringdahl, R. et al. (1979).“Facile Preparation of the Enantiomers of 3-acetoxyquinuclidine and 3-quinuclidinol,”Acta Pharm. Suec.16:281-283.
Saraswati, M. et al. (1994). “Structure-Activity Studies of N,N-Dialkyl and Cycloalkyl Carbamate Esters of Dimethylethanolamine and Choline With Nicotinic and Muscarinic Cholinergic Properties,”Drug Development Research31: 142-146.
Shutske, G.M. (1990). “A Novel Synthesis of the Isoxazolo[5,4,3-kl]acridine Ring System,”J. Heterocyclic Chem.27: 1617-1621.
Waelbroeck, M. et al. (1990). “Binding of Selective Antagonists to Four Muscarinic Receptors (M1to M4) in Rat Forebrain,”Molecular Pharmacology.38: 267-273.
N.N. Godovikov, et al., “Synthesis and muscarinolytic activity of quinuclidinyl benzilate alkyl iodides”, Khim. Farm. Zh., vol. 19, No. 9, pp. 1060-1061, 1985.
J. Lars et al., “Some quinuclidine derivatives with potential antimalarial activity”,Acta Pharm. Suecica, vol. 5, pp. 71-76, 1968.
L. Noronha-Blob et al., “Stereoselective antimuscarinic effects of 3-quinuclidinyl atrolactate and 3-quinuclidinyl xanthene-9-carboxylate”,European Journal of Pharmacology, vol. 221, pp. 97-103, 1992.
S.H. Gao et al., “Stereochemistry of the Heterocyclic Alcohols Containing Piperidine Unit”,Chemical Journal of Chinese Universities, vol. 20, No. 2, pp. 232-236, 1999.
Fryer et al., Am. J. Respir. Crit. Care Med. 158:S154-S160 (1998).

Affiliated with

Also associated with

Rating

Quinuclidine carbamate derivatives and their use as M3... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinuclidine carbamate derivatives and their use as M3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinuclidine carbamate derivatives and their use as M3... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3856643